drugset
drugset / Trial / NCT01896869

FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer

NCT01896869 ↗

Phase 2 Completed 83 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will enroll patients who have metastatic pancreatic cancer with stable disease on FOLFIRINOX chemotherapy. The main purpose of this study is to compare survival between patients that receive ipilimumab and a pancreatic tumor vaccine and patients who continue to receive FOLFIRINOX. Funding Source - FDA Office of Orphan Product Development (OOPD)

Timeline

Start
2013-11
Primary completion
2019-05-03
Completion
2019-05-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Influenza Virus Vaccine Vaccine 5e+08 cells Other
Subject Ipilimumab Monoclonal antibody 3 mg/kg Intravenous
Subject Ipilimumab Monoclonal antibody 10 mg/kg Intravenous

Indications

pancreatic adenocarcinoma